peptide wiki

Sermorelin

aka Geref

Growth Hormone Secretagogues

Mechanism

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the 44-aa native hormone — the shortest fragment that retains full biological activity. It was FDA-approved in the 1990s as Geref (EMD Serono) for diagnostic testing of pituitary GH reserve and later for pediatric idiopathic GH deficiency, but was withdrawn from the US market in 2008–2009 at the manufacturer's request for commercial reasons (not safety or efficacy). It remains on the FDA Category 1 list of bulk substances nominated for use in 503A compounding, where it is now widely prescribed off-label for adult GH insufficiency and "anti-aging" indications.

Identification

CAS number86168-78-7
Molecular formulaC149H246N44O42S
SequenceYADAIFTNSYRKVLGQLSARKLLQDIMSR
Typical dose200-500 mcg/day subcutaneous injection, typically administered at bedtime
Half-life~10-20 minutes (plasma elimination half-life after subcutaneous administration)

Vendors selling Sermorelin

VendorSizePriceListed purityTrust
Peptide Partners 20 mg $115.00 99
Glacier Aminos 10 mg $62.99 99
Crush Research 10 mg $43.00 95
Orbitrex Peptides 10 mg $79.99 95
Profound Aminos 5 mg $43.00 95
Licensed Peptides 5 mg $404.95 95
Licensed Peptides 5 mg $68.99 95
Licensed Peptides 10 mg $68.99 95
Prime Peptides 10 mg $65.00 95
Peptide Tech 5 mg $33.99 94
Mile High Compounds $69.99 94
Hydro Research Peptides 10 mg $0.64 91
Skye Peptides 5 mg $49.00 90
Peptidology 10 mg $79.95 89
Peptide Plugs 10 mg $55.00 89
Qihang Peptide 87
EZ Peptides 5 mg $44.00 85
Simple Peptide 5 mg $49.00 85
Simple Peptide 10 mg $49.00 85
Peptidegurus 2 mg 84
Peptidegurus 5 mg 84
Ascension Peptides 10 mg $72.00 84
Reta Peptide 83
Blank Peptides 10 mg $70.00 81
OROS Research 5 mg 79
OROS Research 5 mg 79
Texpeptide 10 mg $50.00 70
Crystal Peptides 10 mg $59.99 66
Certified Peptides 10 mg $95.00 62
Certified Peptides 5 mg $60.00 62
Nox Amino 10 mg $55.00 55
Peptiatlas 51
MEI-PEPETIDE 2 mg $32.00 48
DongCheng Peptide 46
Mandy 5 mg $56.00 43
HongDa Peptide $80.00 43
MJT peptides 5 mg $73.00 39
HK Peptide Ltd (hk peptides) 37
Cernum Biosciences 5 mg $52.99
Cernum Biosciences 10 mg $79.99
NG Peptide 10 mg $45.00
Strate Labs 10 mg $99.95
AMC Essentials 10 mg $65.99
Alpha Omega 5 mg $49.00
Alpha Omega 10 mg $49.00
Atomik Labz 10 mg $74.00
Atomik Labz 10 mg $64.00
Biotech Peptides 9 mg $88.00
Biotech Peptides 5 mg $43.00
Biotech Peptides 10 mg $81.00
Core Peptides 9 mg $85.00
Core Peptides 10 mg $88.00
Core Peptides 10 mg $88.00
Core Peptides 10 mg $80.00
Core Peptides 5 mg $48.00
Felix Chemical Supply 10 mg $69.99
Flawless Compounds
Genetic Peptide 5 mg $55.00
Genetic Peptide 10 mg $165.00
Genetic Peptide 10 mg $95.00
Genetic Peptide 9 mg $95.00
Genetic Peptide 2 mg $35.00
Genetic Peptide 18 mg $200.00
Ignite Peptides 5 mg $50.00
Kimera Chems $46.99
Modern Research Peptides 5 mg $39.99
Modern Research Peptides 10 mg $46.99
Nextech Labs 10 mg $75.00
Nova Peptides 5 mg $49.99
Paramount Peptides 10 mg $80.00
Peptide Crafters 5 mg $30.00
Peptide Crafters 5 mg $55.00
Peptide Crafters 10 mg $55.00
Peptira $69.00
Pepvida Labs 13 mg $79.00
Polaris Peptides 10 mg $75.00
S1 Research 5 mg $40.00
S1 Research 10 mg $40.00
Solution Peptides 10 mg $74.00
Solution Peptides 10 mg $64.00
Soma Peptides 10 mg $69.00
Southern Aminos 10 mg $74.25
Welli Labs $54.99
Wellness Peptides $55.00

Research

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M. · Frontiers in endocrinology (2026) · review

Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

source →
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM. · Sports medicine (Auckland, N.Z.) (2026) · review

Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.

source →
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
Coutinho LFD, DE Oliveira Neves LF, Camilo RP. · The Journal of sports medicine and physical fitness (2026) · review

The pursuit of pharmacological enhancement in sport has evolved from the widespread use of anabolic-androgenic steroids (AAS) to novel agents such as peptides and peptide analogues.

source →
Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report
Perez SL, Martinez L, Rosselli M, Nair RR. · Frontiers in surgery (2026) · case-report

Background Anterior cervical osteophytes can compress the esophagus, producing dysphagia. Although common on imaging in older adults, symptomatic osteophytic dysphagia is underdiagnosed, and the role of systemic anabolic factors in osteophyte growth is poorly characterized.

source →
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry
Uçaktürk E, Nemutlu E. · Journal of pharmaceutical and biomedical analysis (2026) ·

Growth hormone-releasing hormone (GHRH) and its synthetic analogs are considered performance-enhancing substances and are therefore prohibited by the World Anti-Doping Agency (WADA).

source →
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, Huard J, Philippon MJ. · JBJS reviews (2026) · review

Background Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus.

source →
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA. · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026) · review

Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine.

source →
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. · The American journal of sports medicine (2026) · review

Background Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients.

source →
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L. · International journal of molecular sciences (2026) · review

Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.

source →
Growth hormone - releasing hormone antagonists induce autophagy in cancer cells
Sigdel M, Fakir S, Sarker MMR, Barabutis N. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (2025) ·

GHRH antagonists (GHRHAnt) were developed to suppress cancers and have been associated with robust anti-inflammatory and anti-oxidative activities. The mechanisms involved in those effects are not completely understood.

source →
Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation
· ClinicalTrials.gov (2025) · rct

The goal of this clinical trial is to evaluate a long Clomid protocol as compared to a 5-day Clomid protocol for ovarian stimulation in patients with diminished ovarian reserve undergoing ovarian stimulation for in-vitro fertilization.

source →
Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples
Cristea CD, Radu M, Toboc A, Stan C, David V. · Analytical biochemistry (2023) ·

The use of growth hormone-releasing hormones (GHRHs) is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA). Considering the complexity of urine samples and the low concentrations at which these analytes should be detected, analyzing GHRHs is a challenging task.

source →
In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides
González-López NM, Guerra-Acero-Turizo LM, Blanco-Medina I, Barragán-Cárdenas AC, Ramírez-Celis DA, Martínez-Ramírez JA, Fierro-Medina R, García-Castañeda JE, Rivera-Monroy ZJ. · Biomedical chromatography : BMC (2023) ·

Matrix effect and sample pretreatment significantly affect the percentage recovery of peptides in biological matrices, affecting the method robustness and accuracy. To counteract this effect, an internal standard (IS) is used; however, in most cases this is not available, which limits the analytical method.

source →
Body Composition and Adipose Tissue in HIV
· ClinicalTrials.gov (2018) · rct

In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy.

source →
Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)
· ClinicalTrials.gov (2014) · cohort

The aim of this study is to assess the developmental patterns of lung function in children affected by growth hormone deficiency after one year of GH therapy.The assessment by specific questionnaires of quality of life and of parental stress index.Parameters will be evaluated at the time of the diagnosis and after 12 m…

source →
A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy Volunteers
· ClinicalTrials.gov (2013) · rct

The purpose of this study is to assess the safety,tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of an extended dosing regimen of ITF2984: part A, designed as double-blind, placebo-controlled, randomized, tested an extended dosing regimen, i.e. 14 consecutive dosing days and higher doses, i.e.

source →
Effects of Short-term Growth Hormone in HIV-infected Patients
· ClinicalTrials.gov (2009) · rct

The purpose of this study is to examine the short-term effects of two different doses of growth hormone, compared to treatment with growth hormone releasing hormone, on the brain's secretion of growth hormone and the body's glucose metabolism.

source →
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
· ClinicalTrials.gov (2007) · rct

Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation

source →
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
· ClinicalTrials.gov (2002) · rct

The purpose of this study was to determine whether TH9507, a stabilized analogue of growth hormone-releasing factor (GRF), would have an effect on insulin sensitivity or control of diabetes in patients with type 2 diabetes.

source →
Diagnosing Adult Growth Hormone Deficiency
· ClinicalTrials.gov (2001) · rct

The purpose of this study was to validate the growth hormone releasing hormone (GHRH) plus arginine (GHRH+arg) stimulation test and it´s cut-off limits for diagnosis of adult growth hormone deficiency using the growth hormone (GH) Immulite 2000 Xpi assay calibrated against the IS 98/574 from the World Health Organizati…

source →